Empagliflozin for weight and metabolism in HIV
Treatments studied
Part of Hormones & metabolism, Immune system & allergy, Infections clinical trials.
This trial tests if empagliflozin, a diabetes medicine, can improve weight and metabolism in people with HIV who take dolutegravir and have a high body mass index (BMI). It may help reduce weight gain linked to HIV treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- Your body mass index (BMI) is over 30, meaning you are in the obese range.
- You take a dolutegravir-based HIV medication (an INSTI regimen).
- Your HIV is well-controlled: viral load under 200 copies/mL for at least 6 months and CD4 count above 250.
- You do not have diabetes, significant kidney problems, active hepatitis B or C, or a known thyroid disorder.
- You are not taking other SGLT-2 inhibitors or medications that interact with empagliflozin or dolutegravir.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.
This trial compares two different daily pill combinations for people newly starting HIV treatment who are overweight or have obesity. It aims to see which one works better for controlling the virus and managing weight.
This early-phase trial tests whether an SGLT2 drug can reduce inflammation in belly fat and improve blood vessel function. It may help people with metabolic syndrome prepare for (and potentially benefit around) planned gastric bypass or sleeve surgery.
This trial tests whether a higher dose of empagliflozin works better than the standard dose to treat metabolic syndrome. It may help improve blood sugar and cholesterol-related risk factors in people who meet the trial’s criteria.
This study tests two different medicines (empagliflozin or semaglutide) added to your usual insulin to see if they help with blood sugar control and weight loss in people with type 1 diabetes who are overweight or have obesity. It may be a good fit if your diabetes is not well controlled with insulin injections alone.
This trial compares two medications, dapagliflozin and empagliflozin, to see which works better and is safer for people with type 2 diabetes and a high body mass index (BMI). If you are an adult with type 2 diabetes and a BMI of 23 or higher, this study might help find a treatment that also supports weight loss.
Hear when a new Metabolic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.